About this Research Topic
Lung transplantation stands as a critical option for patients suffering from end-stage diseases such as chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, and cystic fibrosis. While it offers a new lease on life, it also introduces substantial risks including acute rejection, chronic lung allograft dysfunction (CLAD), and complications arising from primary graft dysfunction (PGD) and immunosuppressive treatments, such as infections and bronchial complications like anastomotic leaks.
However, recent strides in pharmacotherapy have significantly improved management outcomes. The use of immunosuppressive drugs such as calcineurin inhibitors, corticosteroids, mTOR inhibitors, and the introduction of newer agents like monoclonal antibodies and targeted therapies are crucial in this advance. These developments not only help prevent rejection and manage CLAD, but also pilot heightened patient-specific treatment plans, aimed at enhancing graft longevity and reducing treatment-related complications.
This Research Topic aims to delve into the complexities and innovations surrounding pharmacotherapy in lung transplantation. Investigating oxidative stress mechanisms and new therapeutic options, assessing advances in immunosuppressive treatments, and reviewing drug interactions will form core objectives.
To gather further insights into pharmacological management in lung transplant medicine, we welcome articles addressing, but not limited to, the following themes:
Mechanisms of oxidative stress during lung ischemia-reperfusion injury
Innovative therapeutics to suppress lung injuries
Immunosuppressive strategies in lung transplantation
Drug interactions and side effects in lung transplantation
The collection seeks contributions in the form of original research articles and review articles that could potentially shape future diagnostic and therapeutic paradigms in lung transplantation care.
However, recent strides in pharmacotherapy have significantly improved management outcomes. The use of immunosuppressive drugs such as calcineurin inhibitors, corticosteroids, mTOR inhibitors, and the introduction of newer agents like monoclonal antibodies and targeted therapies are crucial in this advance. These developments not only help prevent rejection and manage CLAD, but also pilot heightened patient-specific treatment plans, aimed at enhancing graft longevity and reducing treatment-related complications.
This Research Topic aims to delve into the complexities and innovations surrounding pharmacotherapy in lung transplantation. Investigating oxidative stress mechanisms and new therapeutic options, assessing advances in immunosuppressive treatments, and reviewing drug interactions will form core objectives.
To gather further insights into pharmacological management in lung transplant medicine, we welcome articles addressing, but not limited to, the following themes:
Mechanisms of oxidative stress during lung ischemia-reperfusion injury
Innovative therapeutics to suppress lung injuries
Immunosuppressive strategies in lung transplantation
Drug interactions and side effects in lung transplantation
The collection seeks contributions in the form of original research articles and review articles that could potentially shape future diagnostic and therapeutic paradigms in lung transplantation care.
Keywords: Lung transplantation, oxidative stress, immunosuppressive therapy, chronic lung allograft dysfunction, innovative therapeutics
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
